

November 20, 2018



## Syros to Present at 30th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the 30<sup>th</sup> Annual Piper Jaffray Healthcare Conference. Details are as follows:

### **30<sup>th</sup> Annual Piper Jaffray Healthcare Conference**

Date: Tuesday, November 27

Presentation Time: 4:30 p.m. ET

Location: Lotte New York Palace, 455 Madison Avenue, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at [www.syros.com](http://www.syros.com). An archived replay will be available for approximately 30 days following the fireside chat.

### **About Syros Pharmaceuticals**

Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RAR $\alpha$  agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial for patients with ovarian and breast cancers. Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20181120005057/en/>

### **Media Contact:**

Naomi Aoki

Syros Pharmaceuticals

617-283-4298

[naoki@syros.com](mailto:naoki@syros.com)

### **Investor Contact:**

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannahd@sternir.com](mailto:hannahd@sternir.com)

Source: Syros Pharmaceuticals